ADMA
Biotechnology · Healthcare
CFO
2024-04-01–present
Equibles does not estimate personal net worth.
Get an email with a short summary when Adma Biologics, Inc. publishes a filing, an earnings call transcript or a press release.
Get ADMA alertsAdam Grossman is recorded as CFO at Adma Biologics, Inc. (ADMA) since April 1, 2024. Adma Biologics, Inc. reported in an 8-K filed February 28, 2024 that Adam Grossman was appointed Interim Chief Financial Officer, effective April 1, 2024. The proxy statement of Adma Biologics, Inc. reports total compensation of $10,237,326 for Adam Grossman in fiscal 2025, including a base salary of $925,000. Disclosed compensation is on record for 8 fiscal years. Adam Grossman has spoken on 26 earnings calls and 1 other investor event across 1 company, most recently for Adma Biologics, Inc. on August 5, 2026. Adma Biologics, Inc. is classified in the Biotechnology industry within the Healthcare sector. Other leadership on record at Adma Biologics, Inc. includes Jerrold B (CEO and Board Member), Steven A. Elms (Chairman), Brad L. Tade (CFO) and 7 others.
“the Board has appointed Adam Grossman, President and Chief Executive Officer, as Interim Chief Financial Officer, effective as of April 1, 2024.”
“Our second quarter results reflect strong execution across the business and demonstrate the power of Ascentive's long-term growth trajectory.”
“Let me take this opportunity to welcome all those present to this virtual annual meeting of stockholders of ADMA Biologics, Inc. We are excited to be hosting our virtual meeting, which allows us to be more inclusive and reach a greater number of stockholders.”
“We had a strong start to the year with earnings growth and margin expansion despite total revenue being essentially flat. underscoring the resilience of the business.”
“ADMA delivered a strong finish to 2025, reflecting disciplined execution across our commercial, manufacturing, and financial platforms. For the full year, total revenue was $510 million, representing 20% year-over-year growth.”
“ADMA delivered another record quarter of sequential and year-over-year growth, underscoring the strength of our business model and disciplined execution. We delivered total revenue of $134.2 million, representing a 10% quarter-over-quarter increase and 12% growth year-over-year.”
2024-04-01–present
Start not stated–2024-04-15
Last confirmed by a filing; no departure on record
Start not stated–2024-04-15
Last confirmed by a filing; no departure on record
ADMA
Biotechnology · Healthcare
CFO
2024-04-01–present
Compensation components disclosed in company proxy statements. Amounts are nominal USD; total is the company-reported figure.
| Fiscal year | Company | Role | Salary | Total |
|---|---|---|---|---|
| 2025 | Adma Biologics, Inc. (ADMA) | President, Chief Executive Officer and Director | $925,000 | $10,237,326 |
| 2024 | Adma Biologics, Inc. (ADMA) | President, Chief Executive Officer and Director | $800,000 | $7,918,734 |
| 2023 | Adma Biologics, Inc. (ADMA) | Director, President, Chief Executive Officer and Interim Chief Financial Officer | $750,000 | $6,039,649 |
| 2022 | Adma Biologics, Inc. (ADMA) | Director, President, Chief Executive Officer and Interim Chief Financial Officer | $636,540 | $2,649,501 |
| 2021 | Adma Biologics, Inc. (ADMA) | Director, President and Chief Executive Officer | $618,000 | $4,361,250 |
| 2020 | Adma Biologics, Inc. (ADMA) | Director, President and Chief Executive Officer | $600,000 | $1,962,141 |
| 2019 | Adma Biologics, Inc. (ADMA) | Director, President and Chief Executive Officer | $536,000 | $1,702,022 |
| 2018 | Adma Biologics, Inc. (ADMA) | Director, President and Chief Executive Officer | $536,000 | $1,553,300 |